A novel microRNA regulator of prostate cancer epithelial-mesenchymal transition

Cell Death and Differentiation
N BucaySharanjot Saini

Abstract

The most frequent alteration in the prostate oncogenome is loss of chromosome (chr) 8p21 that has been associated with loss of NKX3.1 homeobox gene. Chr8p21 deletions increase significantly with tumor grade and are associated with poor prognosis in prostate cancer (PCa), suggesting critical involvement of this region in tumor progression. Recent studies suggest that apart from NKX3.1, this region harbors alternative tumor suppressors that are yet undefined. We proposed a novel, paradigm shifting hypothesis that this locus is associated with a miRNA gene cluster-miR-3622a/b- that plays a crucial suppressive role in PCa. Here we demonstrate the crucial role of miR-3622a in prostate cancer epithelial-to-mesenchymal transition (EMT). MicroRNA expression profiling in microdissected human PCa clinical tissues showed that miR-3622a expression is widely downregulated and is significantly correlated with poor survival outcome and tumor progression. To understand the functional significance of miR-3622a, knockdown and overexpression was performed using non-transformed prostate epithelial and PCa cell lines, respectively, followed by functional assays. Our data demonstrate that endogenous miR-3622a expression is vital to maintain the epit...Continue Reading

References

Jan 1, 1995·In Vitro Cellular & Developmental Biology. Animal·S W HaywardP Narayan
Jun 28, 2002·Cancer Cell·Dinesh SinghWilliam R Sellers
Aug 22, 2002·Nature Reviews. Cancer·Jean Paul Thiery
Nov 16, 2002·Proceedings of the National Academy of Sciences of the United States of America·George Adrian CalinCarlo M Croce
Dec 24, 2002·The Prostate·Hideyasu MatsuyamaPeter Ekman
Jan 9, 2004·Proceedings of the National Academy of Sciences of the United States of America·Jacques LapointeJonathan R Pollack
Apr 6, 2006·Cancer Research·Nicole S SpoelstraJennifer K Richer
Jun 7, 2006·Proceedings of the National Academy of Sciences of the United States of America·Lin ZhangGeorge Coukos
Sep 27, 2006·The American Journal of Surgical Pathology·Donna E Hansel, Jonathan I Epstein
Sep 19, 2007·Cancer Research·Jacques LapointeJonathan R Pollack
Dec 7, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Karsten GravdalLars A Akslen
Jan 18, 2008·Cancer Research·Simone SpadernaThomas Brabletz
Oct 18, 2008·Cell Cycle·Philip A GregoryGregory J Goodall
Nov 15, 2008·Science·Sooryanarayana VaramballyArul M Chinnaiyan
Jan 21, 2009·Cellular and Molecular Life Sciences : CMLS·C P BrackenG J Goodall
Jun 3, 2009·The Journal of Clinical Investigation·Raghu Kalluri, Robert A Weinberg
Dec 24, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Alexander T El GammalThorsten Schlomm
Jun 29, 2010·Cancer Cell·Barry S TaylorWilliam L Gerald
Dec 17, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sharanjot SainiRajvir Dahiya
Jun 22, 2011·Nature Reviews. Urology·Jones T Nauseef, Michael D Henry
May 9, 2012·Proceedings of the National Academy of Sciences of the United States of America·Wen XueScott W Lowe
Jun 12, 2012·Cancer Metastasis Reviews·Jinsong Zhang, Li Ma
Apr 4, 2013·Science Signaling·Jianjiong GaoNikolaus Schultz
Sep 19, 2015·Journal of Visualized Experiments : JoVE·Nathan BucaySharanjot Saini
Sep 3, 2016·Oncotarget·Kirandeep SekhonSharanjot Saini

❮ Previous
Next ❯

Citations

Nov 23, 2018·International Journal of Molecular Sciences·Yutaro Tsubakihara, Aristidis Moustakas
Feb 14, 2018·Cancer Research·Divya BhagirathSharanjot Saini
Oct 13, 2020·Current Opinion in Endocrine and Metabolic Research·Morgan L ZennerLarisa Nonn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics and Senescence (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may be involved in regulating senescence in cancer cells. This feed captures the latest research on cancer epigenetics and senescence.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.